[Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jason V. Coloma, Chief Executive Officer and Director of Maze Therapeutics (MAZE), was granted 100,000 restricted stock units (RSUs) on 09/22/2025. Each RSU converts to one share of common stock upon settlement and the grant carries a $0 per-share price. The award vests in two equal installments: 50,000 RSUs on September 1, 2026 and 50,000 RSUs on September 1, 2027, contingent on continued service. The RSUs do not have an expiration date and will be cancelled if unvested prior to vesting.

Positive

• 100,000 RSU award granted to the reporting person, providing clear retention incentives
• Defined vesting schedule: 50,000 RSUs vest on September 1, 2026 and 50,000 RSUs vest on September 1, 2027
• RSUs convert 1-for-1 into common stock upon settlement and have no expiration, simplifying administration

Negative

• No performance conditions are disclosed; the award is solely time-based which may be viewed as less aligned with shareholder performance
• Potential dilution from 100,000 shares upon settlement (filing provides no context on total shares outstanding)

Insights

Corporate Governance Expert

TL;DR: CEO received a time-based retention grant of 100,000 RSUs vesting 50/50 over two years, standard for executive retention.

The filing documents a common executive compensation mechanism: a time-based RSU award granted to the CEO who is also a director. Vesting is conditional on continued service with clear 50/50 cliff dates on September 1, 2026 and 2027. The award carries no per-share purchase price and does not expire, which simplifies administration. This appears to be a routine service-based retention grant rather than performance-based compensation; governance stakeholders may note the absence of performance conditions.

Compensation Analyst

TL;DR: 100,000 RSUs at $0 strike, vesting over two years, likely aimed at retention but provides no explicit performance linkage.

From a pay-design perspective, the grant size and 50/50 vesting schedule create near-term and medium-term retention incentives for the CEO. The $0 price and lack of expiration are administrative details consistent with standard RSU practice. Because the award is time-vested only, it may be seen as less directly tied to shareholder outcomes compared with performance-based awards. The filing contains no information on prior holdings or dilution impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Coloma Jason V

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	09/22/2025		A		100,000		(2)	(3)	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

2. The award shall vest as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.

3. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the Form 4 report for MAZE?

The Form 4 reports a grant of 100,000 restricted stock units (RSUs) to Jason V. Coloma on 09/22/2025.

When do the RSUs granted to MAZE CEO vest?

1/2 of the award (50,000 RSUs) vests on September 1, 2026 and the remaining 50,000 vests on September 1, 2027, contingent on continued service.

What is the price and settlement mechanics of the RSUs?

The RSUs have a reported price of $0 and each RSU represents a contingent right to receive one share of common stock upon settlement.

Do the RSUs expire?

No expiration date is disclosed; the filing states the RSUs do not expire and will vest or be cancelled prior to vesting.

Who filed the Form 4 for this transaction?

The reporting person is Jason V. Coloma, listed as Chief Executive Officer and Director of Maze Therapeutics; the form is signed by an attorney-in-fact on 09/24/2025.